Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.
Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5